These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17917290)

  • 1. Improvement of dissolution properties of a new Helicobacter pylori eradicating agent (TG44) by inclusion complexation with beta-cyclodextrin.
    Anzai K; Mizoguchi J; Yanagi T; Hirayama F; Arima H; Uekama K
    Chem Pharm Bull (Tokyo); 2007 Oct; 55(10):1466-70. PubMed ID: 17917290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-dimensional 13C-1H heteronuclear correlation NMR spectroscopic studies for the inclusion complex of cyclomaltoheptaose (beta-cyclodextrin) with a new Helicobacter pylori eradicating agent (TG44) in the amorphous state.
    Anzai K; Kono H; Mizoguchi J; Yanagi T; Hirayama F; Arima H; Uekama K
    Carbohydr Res; 2006 Mar; 341(4):499-506. PubMed ID: 16427035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theoretical study on interactions of β-cyclodextrin with Helicobacter pylori eradicating agent (TG44).
    Jin X; Wang X; Ren C; Miao Y; Yi L
    J Mol Model; 2011 Apr; 17(4):913-20. PubMed ID: 20607331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inclusion complex of 3,9-bis(N,N-dimethylcarbamoyloxy)-5H-benzofuro[3,2-c]quinoline-6-one (KCA-098) with heptakis(2,6-di-O-methyl)-beta-cyclodextrin: interaction and dissolution properties.
    Yamada T; Imai T; Ouchi K; Otagiri M; Hirayama F; Uekama K
    Chem Pharm Bull (Tokyo); 2000 Sep; 48(9):1264-9. PubMed ID: 10993223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The formation of an inclusion complex between a metabolite of ginsenoside, compound K and γ-cyclodextrin and its dissolution characteristics.
    Igami K; Ozawa M; Inoue S; Iohara D; Miyazaki T; Shinoda M; Anraku M; Hirayama F; Uekama K
    J Pharm Pharmacol; 2016 May; 68(5):646-54. PubMed ID: 26255976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study on inclusion complexation of maltosyl-beta-cyclodextrin, heptakis(2,6-di-O-methyl)-beta-cyclodextrin and beta-cyclodextrin with fucosterol in aqueous and solid state.
    Acartürk F; Imai T; Saito H; Ishikawa M; Otagiri M
    J Pharm Pharmacol; 1993 Dec; 45(12):1028-32. PubMed ID: 7908969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of solubility and oral bioavailability of 2-(N-cyanoimino)-5-[(E)-4-styrylbenzylidene]-4-oxothiazolidine (FPFS-410) with antidiabetic and lipid-lowering activities in dogs by 2-hydroxypropyl-beta-cyclodextrin.
    Hara T; Hirayama F; Arima H; Yamaguchi Y; Uekama K
    Chem Pharm Bull (Tokyo); 2006 Mar; 54(3):344-9. PubMed ID: 16508189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cyclodextrins on the solubility and stability of candesartan cilexetil in solution and solid state.
    Al Omari AA; Al Omari MM; Badwan AA; Al-Sou'od KA
    J Pharm Biomed Anal; 2011 Feb; 54(3):503-9. PubMed ID: 20971593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solid-state 13C nuclear magnetic resonance spectroscopic study on amorphous solid complexes of tolbutamide with 2-hydroxypropyl-alpha- and -beta-cyclodextrins.
    Kimura K; Hirayama F; Arima H; Uekama K
    Pharm Res; 1999 Nov; 16(11):1729-34. PubMed ID: 10571279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins.
    Mady FM; Farghaly Aly U
    Drug Des Devel Ther; 2017; 11():1681-1692. PubMed ID: 28652706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process.
    Jun SW; Kim MS; Kim JS; Park HJ; Lee S; Woo JS; Hwang SJ
    Eur J Pharm Biopharm; 2007 Jun; 66(3):413-21. PubMed ID: 17240129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicochemical, in silico and in vivo evaluation of a danazol-beta-cyclodextrin complex.
    Jadhav GS; Vavia PR
    Int J Pharm; 2008 Mar; 352(1-2):5-16. PubMed ID: 18023545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of a novel antimicrobial agent, TG44, for treatment of Helicobacter pylori infection.
    Kamoda O; Anzai K; Mizoguchi J; Shiojiri M; Yanagi T; Nishino T; Kamiya S
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3062-9. PubMed ID: 16940102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation and biological evaluation of glimepiride-cyclodextrin-polymer systems.
    Ammar HO; Salama HA; Ghorab M; Mahmoud AA
    Int J Pharm; 2006 Feb; 309(1-2):129-38. PubMed ID: 16377107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Aqueous Solubility and Antihypercholesterolemic Activity of Ezetimibe on Formulating with Hydroxypropyl-β-Cyclodextrin and Hydrophilic Auxiliary Substances.
    Srivalli KM; Mishra B
    AAPS PharmSciTech; 2016 Apr; 17(2):272-83. PubMed ID: 26077622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of modified cyclodextrins on solubility and percutaneous absorption of celecoxib through human skin.
    Ventura CA; Tommasini S; Falcone A; Giannone I; Paolino D; Sdrafkakis V; Mondello MR; Puglisi G
    Int J Pharm; 2006 May; 314(1):37-45. PubMed ID: 16581211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of aging on crystallization, dissolution and absorption characteristics of amorphous tolbutamide-2-hydroxypropyl-beta-cyclodextrin complex.
    Kimura K; Hirayama F; Arima H; Uekama K
    Chem Pharm Bull (Tokyo); 2000 May; 48(5):646-50. PubMed ID: 10823700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inclusion Complexation of Etodolac with Hydroxypropyl-beta-cyclodextrin and Auxiliary Agents: Formulation Characterization and Molecular Modeling Studies.
    Sherje AP; Kulkarni V; Murahari M; Nayak UY; Bhat P; Suvarna V; Dravyakar B
    Mol Pharm; 2017 Apr; 14(4):1231-1242. PubMed ID: 28248111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of 2-hydroxypropyl-beta-cyclodextrin in an intramuscular injectable preparation of nimodipine.
    Yoshida A; Yamamoto M; Itoh T; Irie T; Hirayama F; Uekama K
    Chem Pharm Bull (Tokyo); 1990 Jan; 38(1):176-9. PubMed ID: 2337940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solid dispersion of hydroxypropyl beta-cyclodextrin and ketorolac: enhancement of in-vitro dissolution rates, improvement in anti-inflammatory activity and reduction in ulcerogenicity in rats.
    Nagarsenker MS; Meshram RN; Ramprakash G
    J Pharm Pharmacol; 2000 Aug; 52(8):949-56. PubMed ID: 11007065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.